Lung Cancer Trial, Recruiting NCT07465848 Sponsor: Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe) Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07465848
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Case Group (people with lung cancer):

  • People who are 45 years of age or older at the time of signing the consent form
  • People who have been diagnosed with small-cell or non-small-cell lung cancer, confirmed through laboratory tissue testing
  • People who have not yet received any cancer treatment (such as surgery, radiation, chemotherapy, or immunotherapy) before their sample is collected

Control Group A (higher-risk people without lung cancer):

  • People who are 45 years of age or older at the time of signing the consent form
  • People considered at high risk for lung cancer, meaning those with a smoking history of at least 20 pack-years who currently smoke or stopped smoking within the last 15 years
  • People with no diagnosis or suspicion of lung cancer, who have had a chest CT scan for lung cancer screening within the past 12 months as part of routine care, and whose scan result showed a LUNG-RADS score of 3 or lower (a low-to-moderate risk rating) (confirm with trial site)

Control Group B (lower-risk people without lung cancer):

  • People who are 45 years of age or older at the time of signing the consent form
  • People who do not meet the high-risk smoking criteria described in Control Group A
  • People with no diagnosis or suspicion of lung cancer

Who may not be able to join:

  • People with a history of any cancer, unless the cancer was caught at an early stage, treated with the intent to cure, and the person has been cancer-free for at least five years
  • People diagnosed with lung cancer who have already started cancer treatment before their sample is collected
  • People who have had a biopsy, invasive procedure, or minor surgery within the last 48 hours
  • People who have had major surgery within the last 7 days
  • People with severe kidney disease, meaning the kidneys are functioning at a very low level (glomerular filtration rate below 15 ml/min) (confirm with trial site)
  • People with severe liver disease, classified as Child-Pugh C (a medical rating indicating advanced liver dysfunction) (confirm with trial site)
  • People who currently have an active infection, or who finished treatment for an infection less than 4 weeks ago
  • People considered part of a vulnerable group, including minors, prisoners, pregnant women, or adults who are not able to give informed consent due to physical or mental incapacity

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 917 56 79 97

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)
Registry
ClinicalTrials.gov
Start date
8 October 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

To determine the risk of developing lung cancer, expressed as a percentage, in order to assist doctors in the diagnosis of lung cancer.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov